
Acconeer: Cash-Flow Sufficient but Delaying Acceleration

Redeye remains firm in its view that Acconeer will not need any additional capital injections. Also, should the need arise, Redeye think Alps Alpine would gladly provide financing to favorable terms. While topline developed poorly in Q3, the strong cash flow should have calmed investors about Acconeer's cash situation. Redeye believes there are several factors under the surface that will make cash flow considerably stronger than EBIT over the next 12 months. Redeye lowers its topline and EBIT estimates for the short- and mid-term and lowers its fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Acconeer: Cash-Flow Sufficient but Delaying Acceleration